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Abstract
Background: Textural features in FDG-PET have been shown to provide prognostic information in a variety of
tumor entities. Here we evaluate their predictive value for recurrence and prognosis in NSCLC patients receiving
primary stereotactic radiation therapy (SBRT).
Methods: 45 patients with early stage NSCLC (T1 or T2 tumor, no lymph node or distant metastases) were included
in this retrospective study and followed over a median of 21.4 months (range 3.1–71.1). All patients were
considered non-operable due to concomitant disease and referred to SBRT as the primary treatment modality.
Pre-treatment FDG-PET/CT scans were obtained from all patients. SUV and volume-based analysis as well as
extraction of textural features based on neighborhood gray-tone difference matrices (NGTDM) and gray-level
co-occurence matrices (GLCM) were performed using InterView Fusion™ (Mediso Inc., Budapest). The ability to
predict local recurrence (LR), lymph node (LN) and distant metastases (DM) was measured using the receiver operating
characteristic (ROC). Univariate and multivariate analysis of overall and disease-specific survival were executed.
Results: 7 out of 45 patients (16%) experienced LR, 11 (24%) LN and 11 (24%) DM. ROC revealed a significant
correlation of several textural parameters with LR with an AUC value for entropy of 0.872. While there was also a
significant correlation of LR with tumor size in the overall cohort, only texture was predictive when examining T1
(tumor diameter < = 3 cm) and T2 (>3 cm) subgroups. No correlation of the examined PET parameters with LN or
DM was shown.
In univariate survival analysis, both heterogeneity and tumor size were predictive for disease-specific survival, but only
texture determined by entropy was determined as an independent factor in multivariate analysis (hazard ratio 7.48,
p = .016). Overall survival was not significantly correlated to any examined parameter, most likely due to the high
comorbidity in our cohort.
Conclusions: Our study adds to the growing evidence that tumor heterogeneity as described by FDG-PET texture is
associated with response to radiation therapy in NSCLC. The results may be helpful into identifying patients who
might profit from an intensified treatment regime, but need to be verified in a prospective patient cohort before
being incorporated into routine clinical practice.
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Background
Hypofractionated stereotactic body radiation therapy
(SBRT) has been shown to be a safe and potentially
curative treatment option in patients with early stage
non-small cell lung cancer (NSCLC) [1-3] and is especially
attractive for patients with a compromised health status
not eligible for surgery. Excellent local control rates of
over 90% – rivaling surgery – have been reported, while
overall survival is considerably lower compared to patients
receiving primary tumor resection, due to significant
comorbidities. Predictive recognition of therapy failure
would be favorable, as this might allow options for
treatment intensification such as simultaneous or
adjuvant chemotherapy, or immunotherapy. However,
identification of tumor recurrence through follow-up
computed tomography (CT) scans is difficult, as imaging
changes due to tumor remnants or radiation reaction may
be visible for prolonged periods after treatment. Similarly,
early post treatment positron emission tomography
(PET) with 18 F-fluorodeoxyglucose (FDG) suffers from
limitations, because radiation-induced reactive changes
such as radiation pneumonitis can cause unspecifically
elevated tracer uptake [4,5]. Some authors suggest that
follow-ups should be delayed until 12 months after initial
therapy in order to reach a sufficient specificity [6,7].
Therefore, the development of surrogate markers for
tumors prone to early recurrence is of particular interest. In
recent studies, maximum uptake of FDG in pre-treatment
PET scans showed a moderate ability to predict overall
survival or local recurrence [8-10], but the relation is weak
and has been questioned in other publications [11,12].
In the recent years, the measurement of spatial heterogen-
eity by methods described as “textural analysis” has gained
attendance as a means to extract predictive information
from FDG-PET scans of several tumors, including sarcoma
[13], head and neck tumors [14] and esophageal carcinoma
[15]. In NSCLC, a histogram-based heterogeneity parameter
has been proposed, but has not been validated on clinical
data [16]. More recently, good results have been reached
with higher-dimensional heterogeneity features, which
have been associated with response and survival after
radiochemotherapy in NSCLC [17,18].
In this study, we wanted to verify these promising results
in patients with early stage NSCLC who received SBRT as
the sole primary treatment modality. Patients included
were considered unsuitable for surgery due to concomitant
disease, mainly affecting pulmonary and cardiac function.
In accordance to earlier publications, textural features
derived from histogram analysis, neighborhood gray-tone
difference matrices (NGTDM) and gray-level co-occurrence
matrices (GLCM) were investigated [19]. We hypothesized
that these parameters may be associated with local re-
currence, mediastinal lymph node or distant metastases,
as well as with overall or disease-specific survival. The
results were compared to ‘classical’ PET parameters like
maximum and mean FDG-uptake and metabolic tumor
volume (MTV).
Methods
Patients
Forty-five consecutive patients with histologically proven
lung malignancy treated with primary SBRT were ana-
lyzed retrospectively. All patients had early stage tumors
(T1 or T2, N0, M0), but were considered not eligible for
surgery due to concomitant disease after discussion in an
interdisciplinary tumor board. All patients received
FDG-PET/CT scans before treatment. Written informed
consent was obtained before each PET scan as part of
the clinical routine. Retrospective analysis of the data
was approved by the local ethical review board of the
Klinikum rechts der Isar der Technischen Universität
München.
PET/CT studies
18 F-FDG PET/CT scans were obtained before start of
treatment using a Biograph 16 PET/CT scanner [20]. To
achieve standardized metabolic conditions, patients
fasted for a minimum of 6 h prior to scanning. Blood
glucose level was <150 mg/dl in all patients before injection.
Studies comprising 6–7 bed positions each for 3 min were
acquired about 60 min after injection of the tracer. Patients
in general received low-dose CTs (24–26 mAs, 120 kV) for
attenuation correction, as contrast enhanced CTs for
morphological correlation were available for all patients
before the examination. Data was reconstructed iteratively
using the ordered subset expectation maximization
algorithm (OSEM) implemented by the manufacturer
including scatter and attenuation correction based on
the CT data using 4 iterations and 16 subsets. The images
were reconstructed into 164 × 164 matrices with a
resulting voxel size of 4.06 by 4.06 mm and a slice
thickness of 5.0 mm.
Image analysis
Image analysis was performed with InterView Fusion
(Mediso Medical Imaging Systems, Budapest, Hungary).
Tumor volumes (volumes of interest - VOIs) were
defined by a 3D standardized uptake value (SUV) 2.0
isocontour around the hottest voxel, with manual
corrections where necessary. For comparison, VOIs
based on SUV 2.5 isocontours were also defined. The
maximum SUV (SUVmax), mean SUV (SUVmean), meta-
bolic tumor volume (MTV), and coefficient of variation
(COV) were calculated on floating-point SUV data. The
SUV used for calculations was the measured activity
concentration normalized to decay corrected injected
activity and body weight of the patient. For determination
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of textural parameters, SUV values were normalized and
discretized to a total of 64 bins by the formula
R xð Þ ¼ 64 I xð Þ−SUVmin½ = SUVmax−SUVmin½ 
where I(x) is the SUV of voxel x in the original image
and R(x) is its resampled value. Subsequently, an analysis
via neighborhood gray-tone difference matrices (NGTDM)
and gray-level co-occurence matrices (GLCM) in 13
directions (3D) was carried out as described earlier [15].
From these matrices, local entropy, correlation, contrast,
coarseness and busyness were derived. Additionally, tumor
diameters were measured in the low-dose CT image.
Radiation treatment and follow-up
Stereotactic radiation therapy was curative in intent and
delivered using a hypofractionated scheme. Treatment
technique and delivery has been previously reported
[21]. Briefly, patients were immobilized in a vacuum
couch and a free-breathing planning CT (either as slow
CT or as 4D-CT) was acquired. In lung window mode,
gross tumor volume (GTV) was delineated and an internal
target volume (ITV) generated according to the breathing
pattern of the patient. Finally, an isotropic margin of 5 mm
axially and 1 cm craniocaudally was added to generate the
planning target volume (PTV). The total administered dose
was 24–45 Gy delivered in 3–5 fractions. Dose was
prescribed to the 60% isodose line which had to cover
the PTV entirely. Tumors measuring less than 5 cm
were treated with 3 fractions of 10–15 Gy (Dmax
16.7 Gy-25 Gy). Larger (>5 cm) or central tumors received
4–5 fractions of 7–8 Gy (Dmax 11.7 Gy – 13.3 Gy). After
treatment, follow-up examinations were scheduled in
intervals of 3–4 months, including chest CT scans.
Statistical analysis
The above-mentioned parameters were tested for their
ability to predict local recurrence (LR), mediastinal lymph
node metastases (LN) and distant metastases (DM) using
receiver operating characteristic (ROC). ROC analysis was
also used to determine thresholds for survival analysis.
Decision thresholds were considered optimal when the
Euclidian distance between the ROC curve and the left
upper corner of the graph reached the minimum. In
addition, for each method the total area under the curve
(AUC) was calculated. For local recurrence, disease-
specific (DSS) and overall survival (OS), Kaplan-Meier
curves were estimated and distributions of survival times
were compared between groups using the log-rank test.
Univariate and Multivariate Cox regression was used for
estimation of hazard ratios (HRs) with 95% confidence
interval (CI). SPSS 22 (IBM Inc., Armonk, NY) was
employed for statistical analysis. A two-sided level of
significance of 5% was used for all tests.
Results
Patients comprised 24 adenocarcinomas and 18 squamous
cell carcinomas. For 3 patients, histology was inconclusive
but small-cell lung cancer could be excluded. Detailed
patient data is given in Table 1.
Local recurrence
LR was observed in 7 patients. Several textural parameters
of heterogeneity, namely entropy, correlation, busyness
and coarseness were able to predict LR on a signifi-
cant level. Areas under the ROC curve were 0.872
(0.770–0.974), 0.816 (0.663–0.969), 0.774 (0.602–0.946)
and 0.774 (0.602–0.946), respectively (see Table 2, Figure 1).
MTV and tumor size measured in CT were also pre-
dictive, with AUC values of 0.806 (0.652–0.960) and
0.739 (0.588 - 0.889) in the whole patient cohort. In con-
trast, no significant associations between SUVmax, SUVmean
or COV and LR could be shown.
As these results suggested a strong dependence of local
recurrence on tumor size, we divided the cohort further
Table 1 Patient characteristics
Patient characteristic Value
Age (years) 74 ± 8.1
Sex (n)
Male 14 (31%)
Female 31 (69%)
T-Stage (n)
T1 15 (33%)
T2 30 (67%)
Histology (n)
Squamous 24 (53%)
Adeno 18 (40%)
Other 3 (7%)
Location (n)
Central 14 (28%)
Peripheral 31 (61%)
GTV (cc) 40.6 (4.2–153)
Movement amplitude (mm) 4.7 ± 2.9*
Tumor size (mm)
T1 24.0 (17.0–30.0)
T2 44.4 (31.0–68.0)
KPS 80 (60–100)
Time of diagnosis 2005–2010
Follow-up (months) 21.4 (3.1–71.1)
Number of deaths (n) 28
Attributed to tumor 12
Other causes 16
GTV - gross tumor volume; KPS - Karnofsky Performance Scale; *obtained by
8 of the patients who had 4D-CT.
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into T1 (diameter < = 3 cm) and T2 subgroups (>3 cm).
All 7 cases of LR were observed in the T2 group, with
entropy and correlation still being able to predict LR
significantly, while busyness, coarseness, SUVmax, MTV
and CT tumor size were no longer predictive (Table 2).
AUCs were 0.801 (0.646 - 0.956) for entropy and 0.776
(0.589 - 0.964) for correlation.
Time to local recurrence was compared between
low- and high-risk groups as determined by ROC analysis.
Again, entropy and correlation showed significant correla-
tions (p < .001 and p < .004) in the log-rank test. Busyness
also revealed a weak, but significant correlation with
time-to-LR (p < .042). The remaining PET parameters
and tumor size were not predictive.
LN and DM occurred in 11 patients, respectively
and were not significantly correlated to any of the
examined conventional or textural PET parameters. The
highest AUCs were found for SUVmean, yielding 0.678
(0.491 - 0.864) for LN and 0.658 (0.464 - 0.851) for DM.
Disease-specific and overall survival
Median follow up was for 21.4 months (range 3.1–71.1).
In ROC analysis, entropy was predictive for disease-
related death which occurred in 12 individuals, while the
feature correlation was significantly associated with
death due to any cause (28 events). No other significant
correlations were revealed in ROC statistics. In survival
analysis, DSS was lower for patients with high entropy
(median survival 25.0 vs. 64.6 months, p = 0.003, see
Table 3 and Figure 2). The other textural parameters as
well as ‘classical’ PET parameters showed no significant
difference in the log-rank test. Similarly, none of the
investigated parameters was significantly correlated with
OS. Univariate Cox regression (see Table 4) showed
significant associations of DSS with entropy, yielding a
HR of 5.92 (CI 1.28–27.39, p = .023) and MTV with a
HR of 1.06 (CI 1.01–1.12, p = .031). Multivariate Cox
regression was executed with a restriction to three
independent variables due to low event numbers.
Textural parameters were tested against MTV as the
best ‘classical’ parameter, tumor size measured in CT and
cumulative dose; similarly, MTV was tested against
entropy and cumulative dose. Results showed only
entropy as a significant, independent factor on DSS with a
HR of 7.48 (CI 1.45–38.7, p = .016). Overall survival was
again not associated with any PET parameter.
Stability and size-dependency
Calculations of the textural parameters described above
were executed on VOIs based on SUV 2.0 isocontours.
In order to estimate their stability with regard to VOI
selection, they were also determined for a SUV 2.5
isocontour. Parameter ranges, correlation coefficients
Table 2 ROC statistics for prediction of recurrence and survival by PET parameters
Parameter LR LR T2 LN DM DSS OS
Entropy .872 (.770 - .974) .801 (.646 - .956) .656 (.476 - .837) .654 (.458 - .849) .729 (.545 - .913) .664 (.496 - .855)
Correlation .816 (.663 - .969) .776 (.589 - .964) .586 (.362 - .809) .572 (.366 - .778) .680 (.503 - .856) .685 (.514 - .855)
Contrast .466 (.272 - .661) .429 (.205 - .652) .528 (.362 - .809) .532 (.344 - .720) .490 (.311 - .688) .408 (.226 - .589)
Busyness .774 (.602 - .946) .702 (.487 - .917) .528 (.335 - .721) .564 (.362 - .766) .630 (.432 - .828) .540 (.359 - .721)
Coarseness .774 (.602 - .946) .702 (.487 - .917) .473 (.362 - .809) .436 (.234 - .638) .370 (.172 - .568) .460 (.279 - .641)
SUVmax .613 (.428 - .797) .559 (.351 - .767) .636 (.456 - .817) .631 (.423 - .839) .612 (.426 - .798) .517 (.335 - .699)
SUVmean .575 (.386 - .764) .516 (.301 - .730) .678 (.491 - .864) .658 (.464 - .851) .633 (.451 - .814) .511 (.325 - .695)
COV .519 (.322 - .715) .460 (.244 - .676) .608 (.398 - .818) .547 (.279 - .814) .544 (.362 - .726) .471 (.286 - .655)
MTV .806 (.652 - .960) .736 (.541 - .931) .557 (.372 - .743) .582 (.374 - .789) .676 (.479 - .872) .630 (.454 - .806)
CT diam. .739 (.588 - .889) .568 (.347 - .790) .547 (.365 - .728) .541 (.352 - .731) .630 (.452 - .808) .620 (.437 - .803)
Shown are AUC values with CI. LR, LN, DM - local, mediastinal lymph node and distant recurrence in all patients; LR T2 - local recurrence in T2 subgroup
(diameter > = 3 cm).
Significant values are printed in bold.
Figure 1 Value of textural and standard PET parameters for
prediction of local recurrence. ROC curves for prediction of local
recurrence through different PET parameters. Coarseness is the
same curve as busyness.
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and levels of significance are shown in Table 5. The results
demonstrate highly significant correlations between the
two VOI definitions for all investigated parameters, with
highest r values for SUV mean (r = .997), COV (r = .996)
and entropy (.996; all p < 0.001; see Figure 3). Naturally,
SUV max was independent of the isocontour used (r = 1).
In order to quantify a possible dependency on PET
volume, the examined parameters were correlated
with MTV (see Table 6). Results showed significant
correlations for all textural parameters except contrast
and COV, with highest r values for coarseness and
busyness (r = 0.747 and 0.860). SUVmax and SUVmean
showed as well significant correlations with MTV (r = 0.341
and 0.318).
Respiratory movement as another potential biasing
factor in textural analysis was assessed in 8 out of 45
patients who received 4D-CT, yielding a medial movement
amplitude of 4.7 ± 2.9 mm (see Table 1).
Discussion
The aim of the present study was to determine
whether textural analysis can provide additional pre-
dictive information regarding recurrence and survival
in NSCLC patients receiving primary SBRT, compared
to classical PET parameters like SUVmax and MTV.
As a result, our data support a possible association
between tumor heterogeneity measured by textural
analysis using entropy, correlation, busyness and
coarseness on baseline FDG PET and local recurrence.
SUVmax and SUVmean, as classical quantitative PET
parameters, were not predictive for LR, which has
already been shown by other authors [10-12], although
one study reported a different result [22]. Another
recent publication showed significance of SUVmax for
prediction of LR only when treated as a continuous
variable in regression analysis but not in the other
statistical tests used [9].
Table 3 Kaplan-Meier analysis of overall and disease-specific survival
Parameter Time to local recurrence (T2) Overall survival Disease-specific survival
Cutoff Low risk High risk P Cutoff Low risk High risk P Cutoff Low risk High risk P
n m n m n m n m n m n m
SUVmax 9.64 0 - 7 19.4 .052 11.2 12 36.0 16 25.2 .161 12.6 4 56.8 8 35.1 .080
SUVmean 4.52 2 52.9 5 48.7 .459 5.02 15 33.7 13 26.7 .283 5.39 6 53.7 6 36.3 .296
Entropy 6.98 0 - 7 16.8 .001 6.83 11 38.3 17 24.8 .111 6.85 2 64.6 10 25.0 .003
Correlation .453 3 61.0 4 10.6 .004 .228 10 39.3 18 25.7 .241 .319 5 55.5 7 34.0 .134
Contrast 231 3 44.8 4 53.1 .980 246 15 28.8 13 31.9 .790 222 4 47.1 8 46.6 .472
Busyness .562 1 65.8 6 40.2 .042 .516 6 38.7 22 28.0 .338 .579 6 52.7 6 25.7 .081
Coarseness .037 2 61.2 5 43.0 .193 .048 9 37.5 19 26.8 .338 .032 6 52.7 6 25.7 .081
COV .522 1 52.8 6 50.3 .579 .669 14 34.0 14 26.6 .411 .527 4 56.5 8 35.5 .101
MTV 44.5 2 61.9 5 19.4 .111 18.0 6 43.4 22 28.3 .436 23.1 4 53.6 8 42.7 .151
CT diameter 39.0 2 58.0 5 48.6 .575 32.5 10 34.6 18 28.0 .235 32.5 3 54.0 9 43.0 .104
n - number of events; m - mean survival.
Significant values are printed in bold.
A B C
G
C
E F H
Figure 2 Survival curves for OS and DSS stratified to different PET parameters. Overall and disease-specific survival of subgroups determined by
SUVmax (A and E), MTV (B and F), busyness (C and G) and entropy (D and H) are shown.
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DSS was significantly linked to PET texture described
by entropy, which is in accordance to earlier studies
showing the predictive value of PET texture for
advanced and early stage NSCLC patients undergoing
combined radio-chemotherapy [18,17]. Maximum or mean
SUV values were not predictive for DSS, contradicting
results by Horne et al. [9], although those were
acquired in a larger cohort. The correlation between
overall survival and the examined PET parameters was
also not significant, most probably due to the large
number of deaths caused by concomitant co-morbidity
(16 patients vs. 12 patients who succumbed to the tumor,
see Table 1). Finally, no parameter was predictive for
the occurrence of mediastinal lymph node or distant
metastases alone, although there have also been reports
on an association with SUV [9,10].
While the homogeneity of the investigated patient cohort
in terms of tumor stage and treatment modality minimizes
bias originating from these factors, the influence of tumor
size is more complex. Although the employed textural
features are designed to be relatively robust against
changes in image resolution, we could demonstrate a
correlation of several textural parameters to MTV, a
dependency which had also been reported by other
authors [23,17]. It should be mentioned here that also
SUVmax and SUVmean were significantly correlated to
Table 4 Effects of variables on OS and DSS
Parameter Overall survival Disease-specific survival
Univariate Multivariate Univariate Multivariate
HR p HR p HR P HR P
Age 1.07 (0.70–1.65) .746 0.78 (0.42–1.44) .424
SUVmax 0.97 (0.72–1.29) .819 1.06 (0.74–1.51) .761
SUVmean 1.00 (0.31–3.25) .994 1.71 (0.37–7.59) .480
High entropy 1.85 (0.85–4.00) .120 1.79 (0.70–4.59)‡ .225 5.92 (1.28–27.4) .023 9.52 (1.39–65.1)‡ .022
High correlation 1.58 (0.72–3.47) .250 2.35 (0.74–7.44) .146 1.61 (0.44–5.90)‡ .474
High contrast 0.90 (0.43–1.92) .793 1.56 (0.46–5.30) .476
High busyness 1.55 (0.62–3.84) .347 2.70 (0.65–8.56) .093 1.29 (0.14–12.2)‡ .822
High coarseness 0.68 (0.30–1.52) .346 0.37 ( 0.12–1.18) .093 0.77 (0.08–7.28)‡ .822
High COV 1.52 (0.71–3.25) .278 2.65 (0.79–8.91) .114 1.98 (0.52–7.53)‡ .401
MTV* 1.02 (0.99–1.06) .223 1.55 (0.27–8.95)† .623 1.06 (1.01–1.12) .031 2.11 (0.12–38.1)† .613
CT diameter 1.01 (0.98–1.04) .555 1.03 (0.98–1.07) .245
†tested against entropy, cumulative dose and CT diameter ‡tested against MTV, cumulative dose and CT diameter.
*analyzed on log scale.
Significant values are printed in bold.
Table 5 Correlation of parameters calculated on SUV 2.0
and SUV 2.5 Iso ROIs
SUV 2.0 SUV 2.5 r P
Range Mean ± SD Range Mean ± SD
SUVmax 3.85-43.1 13.2 ± 6.74 3.85-43.1 13.2 ± 6.74 1 .000
SUVmean 2.44-11.0 5.06 ± 1.66 3.00-12.4 5.71 ± 1.79 .997 <.001
MTV 5.77-204 42.1 ± 46.8 1.74-178 33.9 ± 39.5 .989 <.001
COV .188-.933 .513 ± .144 .132-.839 .438 ± .138 .996 <.001
Entropy 4.58-7.52 6.53 ± .76 4.10-7.56 6.38 ± .84 .996 <.001
Correlation .032-.555 .255 ± .159 -.126-.515 .189 ± .152 .963 <.001
Contrast 13.3-411 234 ± 110 12.2-395 226 ± 105 .990 <.001
Busyness .432-.708 .557 ± .071 .370-.692 .544 ± .072 .933 <.001
Coarseness .007-.104 .044 ± .025 .009-.158 .050 ± .029 .813 <.001
SD - standard deviation.
3
4
5
6
7
8
4 5 6 7 8
S
U
V
 2
.0
 Is
o
 R
O
I
SUV 2.5 Iso ROI
Figure 3 Influence of tumor segmentation. Correlation between
entropy values calculated on SUV 2.0 and SUV 2.5 isocontour VOIs.
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MTV which may be caused to some degree by partial
volume effects [24]. Orhac et al. therefore conclude that
an investigation of the influence of tumor size on the
dependent variables is mandatory [25]. Additionally, in
our study, tumor size alone was predictive for local failure;
LR occurred solely in tumors measuring more than 3 cm.
This association has been reported in earlier studies
as well [21,26] and should be kept in mind as pos-
sibly undermining the correct interpretation of data
on local failure in SBRT, perhaps originating from
insufficient and/or inhomogeneous dose delivery to
larger tumors [27]. However, when only tumors larger
than 3 cm were examined (i. e. T2 tumors), texture
as measured by the features entropy and correlation,
but not MTV or tumor size in CT, were significantly
correlated with LR. Additionally, we performed multivariate
regression analysis with MTV and CT diameter as covari-
ates for survival, showing entropy to be a size-independent
predictor of DSS.
In our opinion, these results suggest that the described
association between FDG-PET texture, recurrence and
survival is not merely a size effect, but also points to
differences in tumor biology. Not much is currently
known about the nature of these differences, however.
Increased heterogeneity in CT tumor images has been
associated with regional variations in hypoxia and angio-
genesis [28], and similar histologic studies should be
performed for FDG texture. A correlation with other
functional imaging modalities, such as advanced MRI
(e. g. diffusion-weighted and perfusion imaging) may pro-
vide additional clues to the biology underlying textural
PET features.
Regarding the choice of heterogeneity parameters,
though, there are still open questions to be answered.
The above-mentioned study by Cook et al. favored
coarseness and busyness as best predictors of overall
survival in the setting of radio-chemotherapy [18]. In
our cohort, which differed in tumor extent (early stage
tumors) and therapy (stereotactic radiation), these
parameters were still predictive for local recurrence,
but did not perform better than MTV and, while signifi-
cant in univariate survival analysis, were not identified
as independent predictors in multivariate analysis.
Instead, local entropy, which has not been investigated by
Cook et al., was the most favorable parameter. Heterogen-
eity determined by entropy has also been shown to be pre-
dictive in low dose CT scans of lung cancer [29] and has
been demonstrated as being relatively robust when exam-
ining inter-study variability [30] and different methods of
tumor segmentation [25]. This robustness was also
confirmed in our cohort, where entropy showed a high
correlation between different VOI definitions (based on
SUV 2.0 vs. SUV 2.5 thresholds), comparable to SUVmean
and MTV. The features correlation and contrast values
also showed a good stability, while r values for busyness
and coarseness were slightly lower, but still significant. In
our view, these results suggest that the examined textural
parameters are stable enough to be of utility for assessing
heterogeneity of lung tumors.
Possible bias in this work also originates from the influ-
ence of respiratory movement on textural measurements
which has not yet been thoroughly evaluated. A recent
study showed moderate differences between gated and
non-gated acquisitions [31], but entropy and correlation
were not included in that investigation, and similar results
have been reported before for standard SUV values
[32]. 8 out of 45 of our patients received 4D-CT enabling
assessment of the movement amplitude which was found
to be in the expected range. Overall, blurring from
respiratory movement is not likely to have a major
effect on the textural parameters determined in our study;
however, respiratory gated PET may be principally
advantageous over ungated measurements in determining
tumor heterogeneity and should be encouraged for com-
parative reasons in future studies on PET texture in lung
tumors.
Our study is limited in being retrospective and by its
relatively small sample size. Higher case numbers and
prospective studies will certainly be needed before
textural analysis on FDG-PET of lung tumors can be
incorporated into routine clinical practice.
Conclusion
Our study adds to the growing evidence that tumor
heterogeneity as described by FDG-PET texture is
associated with response to radiation therapy in NSCLC.
In the future, individual therapy planning may benefit
from these results, by e.g. dose escalation in tumors prone
to local recurrence or by addition of chemotherapy.
However, retrospective design is a major limitation of all
studies published on this topic up to now. Reproducibility
in prospective trials with higher case numbers will be a
prerequisite for the inclusion of PET texture into routine
clinical practice.
Table 6 Correlation of SUV and textural parameters
with MTV
R P
SUVmax 0.341 .022
SUVmean 0.318 .033
Entropy 0.544 <.001
COV .213 .161
Correlation 0.513 <.001
Contrast −0.056 .714
Busyness 0.860 <.001
Coarseness 0.747 <.001
Pyka et al. Radiation Oncology  (2015) 10:100 Page 7 of 9
Abbreviations
AUC: Area under the curve; CI: Confidence interval; COV: Coefficient of
variation; CT: Computed tomography; DM: Distant metastases; DSS:
Disease-specific survival; FDG: 18 F-fluorodeoxyglucose; GTV: Gross tumor
volume; HR: Hazard ratio; LN: Lymph node metastases; LR: Local recurrence;
MTV: Metabolic tumor volume; NSCLC: Non small cell lung cancer;
OS: Overall survival; PET: Positron emission tomography; ROC: Receiver
operating characteristic; SBRT: Stereotactic body radiation therapy;
SUV: Standardized uptake value; SUVmax: Maximum standardized uptake
value; VOI: Volume of interest.
Competing interests
R.B. has a non-commercial research contract with Mediso Medical Imaging
Systems, R.B. is on the speaker’s bureau for Mediso Medical Imaging Systems,
L.P. and N.Z. are employed by Mediso Medical Imaging Systems. No potential
conflicts of interest were disclosed by the other authors.
Authors’ contributions
TP carried out the image analysis and drafted the manuscript; RB designed
the study and helped to draft the manuscript; NA acquired the patients and
participated in the design of the study; BM retrieved and analyzed clinical
data; HS evaluated data on radiation therapy; LP and NZ designed the
software used for image analysis and contributed to the design of the study.
ME conceived of the study and participated in its design and coordination.
All authors read and approved the final manuscript and had full control of
the data submitted for publication.
Acknowledgements
We thank Geoffrey Topping at the Technical University of Munich for the
careful revision of our manuscript.
Author details
1Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar der TU
München, Ismaninger Str, Munich, Germany. 2Klinik und Poliklinik für
Nuklearmedizin, Rheinische Friedrich-Wilhelms-Universität Bonn,
Sigmund-Freud-Straße, Bonn, Germany. 3Klinik für Strahlentherapie und
Radiologische Onkologie, Klinikum rechts der Isar der TU München,
Ismaninger Str, Munich, Germany. 4Klinik für Radio-Onkologie, UniversitätsSpital
Zürich, Rämistrasse, Zurich, Switzerland. 5Mediso Medical Imaging Systems,
Alsotorokvesz, Budapest, Hungary.
Received: 25 November 2014 Accepted: 13 April 2015
References
1. Guckenberger M, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, et al.
Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell
lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.
J Thorac Oncol. 2013;8(8):1050–8.
2. Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of
disease recurrence after stereotactic ablative radiotherapy for early stage
non-small-cell lung cancer: a retrospective analysis. Lancet Oncol.
2012;13(8):802–9.
3. Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, et al. Stereotactic
body radiotherapy for medically inoperable lung cancer: prospective,
single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys.
2012;82(2):967–73.
4. Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, Debrito P, et al.
CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer:
18 F-fluorodeoxyglucose positron emission tomography/computed tomography
serial tumor response assessment. J Hematol Oncol. 2010;3:6.
5. Wiegman EM, Pruim J, Ubbels JF, Groen HJ, Langendijk JA, Widder J.
18 F-FDG PET during stereotactic body radiotherapy for stage I lung
tumours cannot predict outcome: a pilot study. Eur J Nucl Med Mol
Imaging. 2011;38(6):1059–63.
6. Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S, et al.
Differentiation of tumor recurrence from radiation-induced pulmonary
fibrosis after stereotactic ablative radiotherapy for lung cancer:
characterization of 18 F-FDG PET/CT findings. Ann Nucl Med.
2013;27(3):261–70.
7. Essler M, Wantke J, Mayer B, Scheidhauer K, Bundschuh RA, Haller B, et al.
Positron-emission tomography CT to identify local recurrence in stage I lung
cancer patients 1 year after stereotactic body radiation therapy. Strahlenther
Onkol. 2013;189(6):495–501.
8. Takeda A, Yokosuka N, Ohashi T, Kunieda E, Fujii H, Aoki Y, et al. The
maximum standardized uptake value (SUVmax) on FDG-PET is a strong
predictor of local recurrence for localized non-small-cell lung cancer after
stereotactic body radiotherapy (SBRT). Radiother Oncol. 2011;101(2):291–7.
9. Horne ZD, Clump DA, Vargo JA, Shah S, Beriwal S, Burton SA, et al.
Pretreatment SUVmax predicts progression-free survival in early-stage
non-small cell lung cancer treated with stereotactic body radiation therapy.
Radiat Oncol. 2014;9:41.
10. Clarke K, Taremi M, Dahele M, Freeman M, Fung S, Franks K, et al. Stereotactic
body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a
predictor of outcome? Radiother Oncol. 2012;104(1):62–6.
11. Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM. Maximum
standardized uptake value from staging FDG-PET/CT does not predict treatment
outcome for early-stage non-small-cell lung cancer treated with stereotactic
body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(4):1033–9.
12. Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, et al. FDG-PET
and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung
cancer. Lung Cancer. 2007;56(2):229–34.
13. Eary JF, O’Sullivan F, O’Sullivan J, Conrad EU. Spatial heterogeneity in
sarcoma 18 F-FDG uptake as a predictor of patient outcome. J Nucl Med.
2008;49(12):1973–9.
14. Cheng NM, Fang YH, Chang JT, Huang CG, Tsan DL, Ng SH, et al. Textural
features of pretreatment 18 F-FDG PET/CT images: prognostic significance
in patients with advanced T-stage oropharyngeal squamous cell carcinoma.
J Nucl Med. 2013;54(10):1703–9.
15. Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al.
Intratumor heterogeneity characterized by textural features on baseline
18 F-FDG PET images predicts response to concomitant radiochemotherapy
in esophageal cancer. J Nucl Med. 2011;52(3):369–78.
16. van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS,
Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram
method for parameterizing heterogeneous intratumoural FDG uptake in
non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging.
2011;38(9):1636–47.
17. Tixier F, Hatt M, Valla C, Fleury V, Lamour C, Ezzouhri S, et al. Visual versus
quantitative assessment of intratumor 18 F-FDG PET uptake heterogeneity:
prognostic value in Non-small cell lung cancer. J Nucl Med. 2014;55(8):1235–41.
18. Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are
pretreatment 18 F-FDG PET tumor textural features in non-small cell lung
cancer associated with response and survival after chemoradiotherapy?
J Nucl Med. 2013;54(1):19–26.
19. Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying
tumour heterogeneity in 18 F-FDG PET/CT imaging by texture analysis. Eur J
Nucl Med Mol Imaging. 2013;40(1):133–40.
20. Martinez MJ, Bercier Y, Schwaiger M, Ziegler SI. PET/CT Biograph Sensation
16. Performance improvement using faster electronics. Nuklearmedizin.
2006;45(3):126–33.
21. Andratschke N, Zimmermann F, Boehm E, Schill S, Schoenknecht C, Thamm
R, et al. Stereotactic radiotherapy of histologically proven inoperable stage I
non-small cell lung cancer: patterns of failure. Radiother Oncol.
2011;101(2):245–9.
22. Takeda A, Sanuki N, Fujii H, Yokosuka N, Nishimura S, Aoki Y, et al. Maximum
standardized uptake value on FDG-PET is a strong predictor of overall and
disease-free survival for non-small-cell lung cancer patients after stereotactic
body radiotherapy. J Thorac Oncol. 2014;9(1):65–73.
23. Brooks FJ, Grigsby PW. The effect of small tumor volumes on studies of
intratumoral heterogeneity of tracer uptake. J Nucl Med. 2014;55(1):37–42.
24. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging.
J Nucl Med. 2007;48(6):932–45.
25. Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I.
Tumor texture analysis in 18 F-FDG PET: relationships between texture
parameters, histogram indices, standardized uptake values, metabolic
volumes, and total lesion glycolysis. J Nucl Med. 2014;55(3):414–22.
26. Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W, et al. Local control
and toxicity in a large cohort of central lung tumors treated with
stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys.
2014;90(5):1168–76.
Pyka et al. Radiation Oncology  (2015) 10:100 Page 8 of 9
27. Ohri N, Werner-Wasik M, Grills IS, Belderbos J, Hope A, Yan D, et al. Modeling
local control after hypofractionated stereotactic body radiation therapy for
stage I non-small cell lung cancer: a report from the elekta collaborative lung
research group. Int J Radiat Oncol Biol Phys. 2012;84(3):e379–84.
28. Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA. Non-small
cell lung cancer: histopathologic correlates for texture parameters at CT.
Radiology. 2013;266(1):326–36.
29. Mattonen SA, Palma DA, Haasbeek CJ, Senan S, Ward AD. Early prediction of
tumor recurrence based on CT texture changes after stereotactic ablative
radiotherapy (SABR) for lung cancer. Med Phys. 2014;41(3):033502.
30. Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D. Reproducibility
of tumor uptake heterogeneity characterization through textural feature
analysis in 18 F-FDG PET. J Nucl Med. 2012;53(5):693–700.
31. Yip S, McCall K, Aristophanous M, Chen AB, Aerts HJ, Berbeco R. Comparison
of texture features derived from static and respiratory-gated PET images in
Non-small cell lung cancer. PLoS One. 2014;9(12):e115510.
32. Kawano T, Ohtake E, Inoue T. Deep-inspiration breath-hold PET/CT versus
free breathing PET/CT and respiratory gating PET for reference: evaluation in
95 patients with lung cancer. Ann Nucl Med. 2011;25(2):109–16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pyka et al. Radiation Oncology  (2015) 10:100 Page 9 of 9
